Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Pharma Acquires Orphan Medical; Plans Variations On Xyrem

Executive Summary

Jazz Pharmaceuticals is likely to experiment with new formulations of the narcolepsy agent Xyrem (sodium oxybate) after acquiring Orphan Medical

You may also be interested in...



Xyrem gains daytime claim

FDA clears Jazz Pharmaceuticals' Xyrem (sodium oxybate) for treatment of excessive daytime sleepiness in patients with narcolepsy Nov. 18. Xyrem was previously approved for cataplexy in narcolepsy patients. The firm has said that it would seek a general narcolepsy indication; cataplexy and EDS are the two primary symptoms of narcolepsy (1"The Pink Sheet" April 25, 2005, p. 26)...

Xyrem gains daytime claim

FDA clears Jazz Pharmaceuticals' Xyrem (sodium oxybate) for treatment of excessive daytime sleepiness in patients with narcolepsy Nov. 18. Xyrem was previously approved for cataplexy in narcolepsy patients. The firm has said that it would seek a general narcolepsy indication; cataplexy and EDS are the two primary symptoms of narcolepsy (1"The Pink Sheet" April 25, 2005, p. 26)...

Xyrem Risk Management Requires Patient Evaluation Every Three Months

Orphan Medical's risk management program for its cataplexy drug Xyrem will require a patient evaluation by the prescribing physician every three months

Related Content

Topics

UsernamePublicRestriction

Register

PS045716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel